469 related articles for article (PubMed ID: 28750141)
1. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study.
Hallager S; Ladelund S; Kjaer M; Madsen LG; Belard E; Laursen AL; Gerstoft J; Røge BT; Grønbaek KE; Krarup HB; Christensen PB; Weis N
J Viral Hepat; 2018 Jan; 25(1):47-55. PubMed ID: 28750141
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
[TBL] [Abstract][Full Text] [Related]
3. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study.
Nilsson E; Anderson H; Sargenti K; Lindgren S; Prytz H
Scand J Gastroenterol; 2019 Aug; 54(8):1027-1032. PubMed ID: 31389730
[No Abstract] [Full Text] [Related]
4. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort.
Paranaguá-Vezozzo DC; Ono SK; Alvarado-Mora MV; Farias AQ; Cunha-Silva M; França JI; Alves VA; Sherman M; Carrilho FJ
Ann Hepatol; 2014; 13(4):386-93. PubMed ID: 24927609
[TBL] [Abstract][Full Text] [Related]
5. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
6. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.
Hedenstierna M; Nangarhari A; Weiland O; Aleman S
Clin Infect Dis; 2016 Sep; 63(6):723-9. PubMed ID: 27282709
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for hepatocellular carcinoma in patients with liver cirrhosis.
Macías Rodríguez MA; Rendón Unceta P; Tejada Cabrera M; Infante Hernández JM; Correro Aguilar F; Díaz García F; Benítez Rodríguez E; Mangas Rojas A; Martín Herrera L
Rev Esp Enferm Dig; 2000 Jul; 92(7):458-69. PubMed ID: 11026763
[TBL] [Abstract][Full Text] [Related]
8. Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm.
Tayob N; Lok AS; Do KA; Feng Z
Clin Gastroenterol Hepatol; 2016 Mar; 14(3):469-475.e2. PubMed ID: 26260109
[TBL] [Abstract][Full Text] [Related]
9. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H
J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614
[TBL] [Abstract][Full Text] [Related]
10. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study.
Appel-da-Silva MC; Miozzo SA; Dossin IA; Tovo CV; Branco F; de Mattos AA
World J Gastroenterol; 2016 Dec; 22(46):10219-10225. PubMed ID: 28028370
[TBL] [Abstract][Full Text] [Related]
11. [Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].
Petry W; Heintges T; Hensel F; Erhardt A; Wenning M; Niederau C; Häussinger D
Z Gastroenterol; 1997 Dec; 35(12):1059-67. PubMed ID: 9487638
[TBL] [Abstract][Full Text] [Related]
12. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
Masetti C; Lionetti R; Lupo M; Siciliano M; Giannelli V; Ponziani FR; Teti E; Dell'Unto C; Francioso S; Brega A; Montalbano M; Visco-Comandini U; Taibi C; Galati G; Vespasiani Gentilucci U; Picardi A; Andreoni M; Pompili M; Pellicelli AM; D'Offizi G; Gasbarrini A; De Santis A; Angelico M
J Viral Hepat; 2018 Dec; 25(12):1493-1500. PubMed ID: 30112854
[TBL] [Abstract][Full Text] [Related]
13. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study.
Hong TP; Gow PJ; Fink M; Dev A; Roberts SK; Nicoll A; Lubel JS; Kronborg I; Arachchi N; Ryan M; Kemp WW; Knight V; Sundararajan V; Desmond P; Thompson AJ; Bell SJ
Med J Aust; 2018 Oct; 209(8):348-354. PubMed ID: 30309301
[TBL] [Abstract][Full Text] [Related]
14. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.
Reddy KR; McLerran D; Marsh T; Parikh N; Roberts LR; Schwartz M; Nguyen MH; Befeler A; Page-Lester S; Tang R; Srivastava S; Rinaudo JA; Feng Z; Marrero JA
Gastroenterology; 2023 Oct; 165(4):1053-1063.e6. PubMed ID: 37429366
[TBL] [Abstract][Full Text] [Related]
15. Time-trends in incidence and prognosis of hepatocellular carcinoma in Denmark: A nationwide register-based cohort study.
Jepsen P; Andersen MW; Villadsen GE; Ott P; Vilstrup H
Liver Int; 2017 Jun; 37(6):871-878. PubMed ID: 27943604
[TBL] [Abstract][Full Text] [Related]
16. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
[TBL] [Abstract][Full Text] [Related]
17. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
[TBL] [Abstract][Full Text] [Related]
19. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Aliment Pharmacol Ther; 2018 Jan; 47(1):104-113. PubMed ID: 29035002
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study.
Alacacioglu A; Somali I; Simsek I; Astarcioglu I; Ozkan M; Camci C; Alkis N; Karaoglu A; Tarhan O; Unek T; Yilmaz U
Jpn J Clin Oncol; 2008 Oct; 38(10):683-8. PubMed ID: 18753360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
